Dual acting polymeric nano-aggregates for liver cancer therapy

Wejdan Al Shakarchi, Ali Alsuraifi, Anthony Curtis, Clare Hoskins

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug.
Original languageEnglish
Article number63
Number of pages13
JournalPharmaceutics
Volume10
Issue number2
DOIs
Publication statusPublished - 26 May 2018

Fingerprint

Cytochromes
Liver Neoplasms
Liver
Paclitaxel
Nanoparticles
Gold
Self assembly
Allylamine
Cells
Pharmaceutical Preparations
Amphiphiles
Apoptosis Regulatory Proteins
Oncology
Therapeutics
Cytotoxicity
Encapsulation
Sulfhydryl Compounds
Toxicity
Polymers
Protein C

Keywords

  • combination therapy
  • paclitaxel
  • liver cancer
  • hybrid nanoparticles
  • drug delivery

Cite this

Al Shakarchi, Wejdan ; Alsuraifi, Ali ; Curtis, Anthony ; Hoskins, Clare. / Dual acting polymeric nano-aggregates for liver cancer therapy. In: Pharmaceutics. 2018 ; Vol. 10, No. 2.
@article{67458dffb66b4b8a8ac192ca0de93ca9,
title = "Dual acting polymeric nano-aggregates for liver cancer therapy",
abstract = "Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug.",
keywords = "combination therapy, paclitaxel, liver cancer, hybrid nanoparticles, drug delivery",
author = "{Al Shakarchi}, Wejdan and Ali Alsuraifi and Anthony Curtis and Clare Hoskins",
year = "2018",
month = "5",
day = "26",
doi = "10.3390/pharmaceutics10020063",
language = "English",
volume = "10",
journal = "Pharmaceutics",
issn = "1999-4923",
number = "2",

}

Dual acting polymeric nano-aggregates for liver cancer therapy. / Al Shakarchi, Wejdan; Alsuraifi, Ali; Curtis, Anthony; Hoskins, Clare.

In: Pharmaceutics, Vol. 10, No. 2, 63, 26.05.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dual acting polymeric nano-aggregates for liver cancer therapy

AU - Al Shakarchi, Wejdan

AU - Alsuraifi, Ali

AU - Curtis, Anthony

AU - Hoskins, Clare

PY - 2018/5/26

Y1 - 2018/5/26

N2 - Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug.

AB - Liver cancer treatments are often hindered by poor drug physicochemical properties, hence there is a need for improvement in order to increase patient survival and outlook. Combination therapies have been studied in order to evaluate whether increased overall efficacy can be achieved. This study reports the combined treatment of liver cancer cells with a combination treatment of chemotherapeutic agent paclitaxel and pro-apoptotic protein cytochrome C. In order to administer both agents in a single formulation, a poly(allylamine)-based amphiphile has been fabricated with the incorporation of a hybrid iron oxide-gold nanoparticle into its structure. Here, the insoluble paclitaxel becomes incorporated into the hydrophobic core of the self-assemblies formed in an aqueous environment (256 nm), while the cytochrome C attaches irreversibly onto the hybrid nanoparticle surface via gold-thiol dative covalent binding. The self-assemblies were capable of solubilising up to 0.698 mg/mL of paclitaxel (700-fold improvement) with 0.012 mg/mL of cytochrome C also attached onto the hybrid iron oxide-gold nanoparticles (HNPs) within the hydrophobic core. The formulation was tested on a panel of liver cancer cells and cytotoxicity was measured. The findings suggested that indeed a significant improvement in combined therapy (33-fold) was observed when compared with free drug, which was double the enhancement observed after polymer encapsulation without the cytochrome C in hepatocellular carcinoma (Huh-7D12) cells. Most excitingly, the polymeric nanoparticles did result in improved cellular toxicity in human endothelian liver cancer (SK-hep1) cells, which proved completely resistant to the free drug.

KW - combination therapy

KW - paclitaxel

KW - liver cancer

KW - hybrid nanoparticles

KW - drug delivery

U2 - 10.3390/pharmaceutics10020063

DO - 10.3390/pharmaceutics10020063

M3 - Article

VL - 10

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 2

M1 - 63

ER -